Position in SEPN
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$13,295,030
-$2,130,081 QoQ
Shares Held
553,268
0.0% QoQ
Ownership
1.23%
of shares outstanding
% of Portfolio
1.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2024
6 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in SEPN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Casdin Capital, LLC holds $705,487,766 across 26 Biotechnology names. SEPN ranks #12 (1.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RVMD |
Revolution Medicines, Inc.
|
2,577,333 | $250,645,634 | |
| 2 | RLAY |
Relay Therapeutics, Inc.
|
14,418,574 | $143,464,811 | |
| 3 | GPCR |
Structure Therapeutics Inc.
|
1,175,000 | $56,635,000 | |
| 4 | DNLI |
Denali Therapeutics Inc.
|
1,840,000 | $35,328,000 | |
| 5 | BEAM |
Beam Therapeutics Inc.
|
1,350,000 | $32,170,500 | |
| 6 | NGNE |
Neurogene Inc.
|
1,420,361 | $28,634,477 | |
| 7 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
75,000 | $24,815,250 | |
| 8 | MAZE |
Maze Therapeutics, Inc.
|
758,857 | $22,651,881 |
All Filings in SEPN
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $13,295,030 | 553,268 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $15,425,111 | 553,268 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $10,406,971 | 553,268 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $5,848,042 | 553,268 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $3,203,421 | 553,268 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $12,669,837 | 553,268 | Shares | Sole | 2025-02-14 | |
| No filing history on record for this holder in this stock. | ||||||